Sildenafil Powder, For Suspension
Product Images NDC 69238-1574

17 FDA label images from Amneal Pharmaceuticals Ny Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 69238-1574). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Sildenafil For Oral Suspension 1)

Structural Formula (Sildenafil For Oral Suspension 1)
An instructional illustration showing a syringe drawing liquid from a medicine vial, accompanied by a graduated measuring cylinder. The syringe is marked with volume units, and the image suggests a measurement or preparation step for oral liquid medication.*
FDA Label Image

1 (Sildenafil For Oral Suspension 2)

1 (Sildenafil For Oral Suspension 2)
An instructional illustration showing a bottle being prepared for use: a hand pushing down and twisting the cap to open, another hand holding the bottle and shaking it up and down, and a stopwatch indicating a 30-second wait time.*
FDA Label Image

2 (Sildenafil For Oral Suspension 3)

2 (Sildenafil For Oral Suspension 3)
An instructional illustration showing a graduated measuring cylinder filled with liquid, a vial containing liquid medication, and an oral dosing syringe marked with volume graduations. These components are typically used for measuring and administering Sildenafil powder for suspension oral liquid at a 10 mg/mL concentration.*
FDA Label Image

3 (Sildenafil For Oral Suspension 4)

3 (Sildenafil For Oral Suspension 4)
An instructional illustration showing the steps to prepare a medication bottle for use: twisting the cap open, shaking the bottle up and down, and using a timer to monitor a 15-minute period.*
FDA Label Image

4 (Sildenafil For Oral Suspension 5)

4 (Sildenafil For Oral Suspension 5)
An instructional diagram showing steps to prepare an oral suspension from a powder bottle. The first step depicts placing a cap on the bottle, and the second shows twisting or mixing the bottle with the cap on to reconstitute the powder into suspension.*
FDA Label Image

5 (Sildenafil For Oral Suspension 6)

5 (Sildenafil For Oral Suspension 6)
A line graph showing estimated cumulative mortality rate (%) over time (years) comparing high, medium, and low doses. The graph includes counts of subjects at risk at various time points and depicts higher mortality rates with increased dose levels.*
FDA Label Image

1 (Sildenafil For Oral Suspension 7)

1 (Sildenafil For Oral Suspension 7)
Chemical structure of Sildenafil. The image displays the molecular formula diagram showing the arrangement of atoms and bonds characteristic to Sildenafil, consistent with the active ingredient in the human prescription drug Sildenafil powder for suspension, 10 mg/mL, by Amneal Pharmaceuticals NY LLC.*
FDA Label Image

B (Sildenafil For Oral Suspension 8)

B (Sildenafil For Oral Suspension 8)
A dot plot chart showing fold change and 90% confidence intervals for various interacting drugs on parameters AUC and Cmax relative to Sildenafil alone. Drugs listed include Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir. Recommendations for dose adjustments or coexistence are provided, mostly stating 'No dose adjustment' except Ritonavir, where coadministration is not recommended. The chart indicates pharmacokinetic interactions with Sildenafil 10 mg/mL oral powder for suspension by Amneal Pharmaceuticals.*
FDA Label Image

C (Sildenafil For Oral Suspension 9)

C (Sildenafil For Oral Suspension 9)
A forest plot chart showing fold change and 90% confidence intervals for various interacting drugs with sildenafil, including Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin (three doses), Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. The chart includes recommendations for dose adjustment, mostly indicating no dose adjustment needed, except Ritonavir which shows coadministration not recommended.*
FDA Label Image

D (Sildenafil For Oral Suspension 10)

D (Sildenafil For Oral Suspension 10)
A line graph showing change from baseline over 12 weeks for four study groups: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID. The y-axis represents change from baseline in units, and the x-axis shows weeks 4, 8, and 12 of the study. Data points include error bars indicating variability.*
FDA Label Image

E (Sildenafil For Oral Suspension 11)

E (Sildenafil For Oral Suspension 11)
A forest plot displaying placebo-corrected changes in 6-minute walk distance (meters) for Sildenafil 20 mg three times daily across various patient subgroups including baseline walk distance, etiology, pulmonary hypertension class, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index. Each subgroup shows data points with confidence intervals comparing Sildenafil and placebo groups.*
FDA Label Image

F (Sildenafil For Oral Suspension 12)

F (Sildenafil For Oral Suspension 12)
A line graph displaying the percentage of subjects without a clinically worsening event over time. The x-axis represents days from randomization, ranging from 0 to 112 days. Two curves are shown, one for placebo and one for Sildenafil, tracking their respective percentages throughout the study period.*
FDA Label Image

G (Sildenafil For Oral Suspension 13)

G (Sildenafil For Oral Suspension 13)
A line graph showing mean change from baseline in meters over 12 weeks of study for Sildenafil oral doses of 1 mg TID, 5 mg TID, and 20 mg TID. The y-axis represents change from baseline in meters, and the x-axis represents weeks 4, 8, and 12. Standard error bars are shown for each dose at every time point.*
FDA Label Image

H (Sildenafil For Oral Suspension 14)

H (Sildenafil For Oral Suspension 14)
An instructional illustration showing a bottle of Sildenafil powder for oral suspension labeled with a cap and syringe adaptor. Next to it is a syringe labeled with parts: tip, barrel with 1.5 and 2 mL markings, and plunger, indicating components for measuring and administering the suspension.*
FDA Label Image

I (Sildenafil For Oral Suspension 15)

I (Sildenafil For Oral Suspension 15)
An instructional illustration showing hands preparing a medication bottle for use. The first image demonstrates shaking the bottle up and down and side to side. The center image is a stopwatch indicating wait time. The third image shows twisting and pushing down the bottle cap to open. This likely relates to preparing Sildenafil powder for suspension.*
FDA Label Image

1 (Sildenafil For Oral Suspension 16)

1 (Sildenafil For Oral Suspension 16)
An instructional illustration labeled 'Figure C' showing a person holding a bottle with one hand and using the other hand to pull up on a syringe attached to the bottle's top. The syringe has volume markings, indicating it is being used to draw liquid from the bottle, consistent with preparation of an oral suspension.*
FDA Label Image

2 (Sildenafil For Oral Suspension 17)

2 (Sildenafil For Oral Suspension 17)
An instructional illustration showing a hand holding a bottle upside down and drawing liquid into a syringe. The syringe is marked with volume measurements. The figure is labeled as 'Figure D' and demonstrates the process of drawing a suspension from the bottle.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.